HeartBeam is developing the AIMIGo™ - a credit card-sized cardiac monitoring device that synthesizes a 12-lead ECG.

The HeartBeam AIMIGo™ has not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA or other geographies.

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Company Overview

HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company that is dedicated to transforming cardiac care through the power of personalized insights. The company’s proprietary vectorelectrocardiography (VECG) technology collects 3D signals of the heart’s electrical activity and converts them into a 12-lead ECG. This platform technology is designed to be used on portable, patient-friendly devices such as a credit-card sized monitor, watch or patch. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining how cardiac health is managed in the future.

View Management Team View Board of Directors

Investor Contact Information


HeartBeam, Inc.
2118 Walsh Avenue
Suite 210
Santa Clara, CA 95050
T: 408-899-4443

Investor Relations

MZ North America
Chris Tyson
Executive Vice President
T: 949-491-8235

Transfer Agent

VStock Transfer
18 Lafayette Place
Woodmere, NY 11598